LCG
LGND icon

Lisanti Capital Growth’s Ligand Pharmaceuticals LGND Stock Holding History

Lisanti Capital Growth’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.93M Sell
18,747
-19,865
-51% -$4.68M 1.3% 28
2026
Q1 		$7.71M Sell
38,612
-5,130
-12% -$1.01M 1.94% 8
2025
Q4 		$8.27M Buy
43,742
+14,065
+47% +$2.7M 1.96% 3
2025
Q3 		$5.26M Buy
29,677
+19,002
+178% +$2.82M 1.29% 30
2025
Q2 		$1.21M Sell
10,675
-41,900
-80% -$4.48M 0.34% 90
2025
Q1 		$5.53M Buy
52,575
+13,565
+35% +$1.53M 1.64% 13
2024
Q4 		$4.18M Buy
39,010
+14,225
+57% +$1.61M 1.01% 42
2024
Q3 		$2.48M Buy
+24,785
New +$2.5M 0.63% 70
2019
Q1 		– Sell
-17,601
Closed -$1.49M – 124
2018
Q4 		$1.49M Sell
17,601
-8,496
-33% -$906K 0.6% 67
2018
Q3 		$4.47M Buy
26,097
+3,166
+14% +$477K 1.55% 16
2018
Q2 		$2.96M Buy
22,931
+1,555
+7% +$174K 1.13% 34
2018
Q1 		$2.2M Buy
+21,376
New +$2.11M 1.06% 40
2016
Q3 		– Sell
-11,421
Closed -$850K – 102
2016
Q2 		$850K Sell
11,421
-2,237
-16% -$166K 1.28% 29
2016
Q1 		$912K Buy
13,658
+10,204
+295% +$620K 1.08% 40
2015
Q4 		$234K Buy
+3,454
New +$213K 0.25% 88
2014
Q2 		– Sell
-52,394
Closed -$2.2M – 105
2014
Q1 		$2.2M Buy
52,394
+19,893
+61% +$829K 0.95% 56
2013
Q4 		$1.07M Buy
+32,501
New +$1.06M 0.45% 82
2013
Q3 		– Sell
-40,388
Closed -$1.19M – 105
2013
Q2 		$1.19M Buy
+40,388
New +$726K 0.57% 69

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lisanti Capital Growth's LGND Position: Q2 2026 in Review

Lisanti Capital Growth reduced its Ligand Pharmaceuticals (LGND) stake by 51% in Q2 2026, selling an estimated $4.68M and leaving 18,747 shares worth $5.93M. The position accounts for 1.3% of the portfolio, ranked #28.

Lisanti Capital Growth first reported a position in LGND in Q2 2013 and has held it in 18 quarters since. The position peaked at $8.27M in Q4 2025. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Lisanti Capital Growth held 18,747 shares of Ligand Pharmaceuticals worth $5.93M as of Q2 2026.
  • Lisanti Capital Growth sold 19,865 Ligand Pharmaceuticals shares in Q2 2026, an estimated $4.68M.
  • Ligand Pharmaceuticals made up 1.3% of Lisanti Capital Growth's portfolio in Q2 2026, its #28 holding.
  • Lisanti Capital Growth first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
  • Lisanti Capital Growth's Ligand Pharmaceuticals position peaked at $8.27M in Q4 2025.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Lisanti Capital Growth's 13F filing for Q2 2026, filed 10 Aug 2026.